rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

MetaVia Inc.

MTVA · Nasdaq

Health CareBiotechnologyNot moving yet

MTVA stood above a rising 150-day average in 3 of the last 52 weekly readings, and has been out of that trend for the last 41 weeks. It is 24.5% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 41
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
16 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 3 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$3.2MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders16+4 on the quarter
New · exited4 · 0
Reported value$371K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
JANE STREET GROUP, LLCadded · filed 14 Aug 2026123,583$177K+112,680+1033.5%
CITADEL ADVISORS LLCnew · filed 14 Aug 202661,206$88K+61,206
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202621,314$30K-12,321−36.6%
UBS Group AGadded · filed 13 Aug 202612,948$19K+12,947+1294700.0%
Scientech Research LLCnew · filed 14 Aug 202612,014$17K+12,014
Aries Wealth Managementunchanged · filed 24 Jul 202610,000$14K00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20268,919$13K+6,697+301.4%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 20266,940$9,92400.0%
Tower Research Capital LLC (TRC)reduced · filed 11 Aug 20262,223$3,179-379−14.6%
SBI Securities Co., Ltd.added · filed 23 Jul 2026270$386+65+31.7%
31 Dec 2025 – 30 Jun 2026
111416Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Sarah Kaplan Browne Company insiderChief Medical Officer · last 12 Oct 20260 · 0
Andrew I. Koven Company insiderDirector · last 8 Jun 20260 · 0
D. Gordon Strickland Company insiderDirector · last 8 Jun 20260 · 0
James Patrick Tursi Company insiderDirector · last 8 Jun 20260 · 0
Jason L. Groves Company insiderDirector · last 8 Jun 20260 · 0
Mark A. Glickman Company insiderDirector · last 8 Jun 20260 · 0
Michael Salsbury Company insiderDirector · last 8 Jun 20260 · 0
Hyung Heon Kim Company insiderCEO & President · last 23 Jan 20260 · 0
Marshall H. Woodworth Company insiderChief Financial Officer · last 23 Jan 20261 · 0
Dong-A St Co., Ltd Company insider10% owner · last 8 May 20253 · 1
Na Yeon Kim Company insiderDirector, 10% owner · last 27 Jul 20230 · 0
E&healthcare Investment Fund Ii Company insider10% owner · last 26 Jul 20220 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Interest coverFY 2025 · to 31 Dec 2025-26.88×
Share count trendFY 2025 · to 20 Mar 2026121%
Cash and equivalentsFY 2025 · to 31 Dec 2025$10.3M
Free cash flowFY 2025 · to 31 Dec 2025−$15.7M

Analyst forecasts

No analyst forecasts yet.